Drug interactions
Lorlatinib + Vincristine liposomal
Severity: Moderate
Lorlatinib and Vincristine liposomal: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a moderate CYP3A4 inducer and may lower exposure to vincristine, which is cleared mainly through CYP3A4. Reduced vincristine exposure could weaken antineoplastic efficacy. The clinical significance with the liposomal formulation is not well characterised.
What this interaction means in plain words
Lorlatinib and Vincristine liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Lorlatinib induces CYP3A4 and may increase the metabolic clearance of vincristine.
What to do
Monitor the response to chemotherapy and consider an alternative to lorlatinib if possible. Watch for loss of efficacy and review the regimen with the oncology team.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Vincristine liposomal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Vincristine liposomal?
MediHelp rates the interaction as moderate. Lorlatinib and Vincristine liposomal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib is a moderate CYP3A4 inducer and may lower exposure to vincristine, which is cleared mainly through CYP3A4. Reduced vincristine exposure could weaken antineoplastic efficacy. The clinical significance with the liposomal formulation is not well characterised.
How serious is the interaction between Lorlatinib and Vincristine liposomal?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor the response to chemotherapy and consider an alternative to lorlatinib if possible. Watch for loss of efficacy and review the regimen with the oncology team.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
